

Neurotech Receives \$1.2M R&D Tax Rebate

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the receipt of a \$1.189 million R&D Tax Incentive rebate for the 2022 financial year.

The R&D Tax Incentive funds received will be invested into the Company's clinical pipeline, which now consists of multiple, parallel Phase I/II and Phase II/III clinical trials for NTI164 in paediatric neurological disorders including Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) / Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and cerebral palsy (CP).

Dr Thomas Duthy, Executive Director of Neurotech said "We are very pleased to have received the \$1.2 million R&D Tax Incentive, which along with the recent \$9.0 million share placement, materially strengthens our capital position and fully funds our three new clinical trials in ASD, PANDAS/PANS and CP, while also supporting our existing ASD patients who are continuing to receive NTI164 as part of the Phase I/II extension study."

The Research and Development Tax Incentive (R&D Tax Incentive or R&DTI) helps companies innovate and grow by offsetting some of the costs of eligible research and development (R&D).

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY23. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.